Alert label

Alert

Alert Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

For occasional use only 

Do not use

  • in children under 12 years
  • as a substitute for sleep 
Caffeine Warning:

The recommended dose of this product contains about as much caffeine as a cup of coffee. Limit the use of caffeine-containing medications, foods, or beverages while taking this product because too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heart beat.

Stop use and ask a doctor if

fatigue or drowsiness persists or continues to recur 

If pregnant or breast-feeding,

ask a health professional before use. 

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away. 

Do not use

  • in children under 12 years
  • as a substitute for sleep 

Stop use and ask a doctor if

fatigue or drowsiness persists or continues to recur 

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

helps restore mental alertness or wakefulness when experiencing fatigue or drowsiness 

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Alert Manufacturers

  • L.n.k. International, Inc.
    Alert | L.n.k. International, Inc.
    No Recall

    Alert | L.n.k. International, Inc.

    Alert | L.n.k. International, Inc.
    adults and children 12 years and over: take 1 tablet not more often than every 3 to 4 hours
  • Time Cap Labs, Inc
    Alert | Time Cap Labs, Inc
    No Recall

    Alert | Time Cap Labs, Inc

    Alert | Time Cap Labs, Inc
    Directions
    adults and children 12 years and over: take 1 tablet not more often than every 3 to 4 hours
  • Dolgencorp, Llc
    Alert | Mylan Pharmaceuticals Inc.
    No Recall

    Alert | Mylan Pharmaceuticals Inc.

    Alert | Mylan Pharmaceuticals Inc.
    Essential Hypertension

    The dose of verapamil hydrochloride extended-release capsules should be individualized by titration. The usual daily dose of extended-release verapamil hydrochloride capsules in clinical trials has been 240 mg given by mouth once daily in the morning. However, initial doses of 120 mg a day may be warranted in patients who may have an increased response to verapamil (e.g., elderly, small people, etc.). Upward titration should be based on therapeutic efficacy and safety evaluated approximately 24 hours after dosing. The antihypertensive effects of verapamil hydrochloride extended-release capsules are evident within the first week of therapy.

    If adequate response is not obtained with 120 mg of verapamil hydrochloride extended-release capsules, the dose may be titrated upward in the following manner:

    • 180 mg in the morning, • 240 mg in the morning, • 360 mg in the morning, • 480 mg in the morning.

    Verapamil extended-release capsules are for once a day administration. When switching from immediate-release verapamil to verapamil hydrochloride extended-release capsules, the same total daily dose of verapamil hydrochloride extended-release capsules can be used.

    As with immediate-release verapamil, dosages of verapamil hydrochloride extended-release capsules should be individualized and titration may be needed in some patients.

    Sprinkling the Capsule Contents on Food

    Verapamil hydrochloride extended-release bead filled capsules may also be administered by carefully opening the capsule and sprinkling the beads on a spoonful of applesauce. The applesauce should be swallowed immediately without chewing and followed with a glass of cool water to ensure complete swallowing of the beads. The applesauce used should not be hot, and it should be soft enough to be swallowed without chewing. Any bead/applesauce mixture should be used immediately and not stored for future use. Subdividing the contents of a verapamil hydrochloride extended-release capsule is not recommended.